Medical technology company Vector Science & Therapeutics (TSXV: PAIN) announced on Monday that it has entered a three-year development and manufacturing agreement with MPP Group LLC to support the production of pharmaceutical-grade peptides and drug delivery devices within a single FDA-registered, cGMP-compliant facility.

This collaboration will give Vector access to MPP's Mequon, Wisconsin facility, enabling integrated formulation, analytical testing and manufacturing for up to 24 novel shelf-stable peptide formulations. The structure is designed to accelerate development timelines and support entry into the estimated USD80.8bn peptide market.

The agreement includes joint development of 22 peptide formulations with stability of up to 24 months, including compounds such as BCP-157, Retatrutide, Semaglutide-related peptides, Ipamorelin and others. Fourteen of the peptides have recently been reinstated for compounding eligibility under physician supervision following regulatory changes.

Vector will fund dedicated manufacturing equipment, which it will own and retain rights to in the event of termination. The companies will also jointly develop proprietary purity and potency testing methods, which will be maintained as trade secrets.

Formulation development and initial manufacturing activities are scheduled to begin in May 2026. Vector Science & Therapeutics develops drug delivery platforms focused on site-directed therapeutic applications, while MPP Group provides contract development and manufacturing services for pharmaceutical clients.